



PRESS RELEASE

Crucell Analyst Briefing Update

Leiden, The Netherlands, April 26, 2006 – Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) has invited investors, the media and the general public to access a live audio webcast of an analyst briefing set to take place at 2.00pm CET (8.00am US Eastern time) on Thursday, April 27, 2006.

Prior to the meeting, at 1.00pm CET, Crucell will issue a press release providing details of the developments the Management Board will discuss during its comprehensive update on the Company's programs, market developments and the integration of the recently acquired Berna Biotech AG.

The live audio webcast, featuring the presentation slides, can be accessed via the homepage of Crucell's website at www.crucell.com, and will be archived and available for replay following the event. The briefing is expected to last approximately two hours.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes vaccines against hepatitis B and virosomal influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6[®] production technology. The Company licences this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, elsewhere in Europe, and in Korea. The Company employs about 900 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.

Harry Suykerbuyk
Director Investor Relations and
Corporate Communications
Tel. +31-(0)71-524 8718
h.suykerbuyk@crucell.com

For Crucell in the US:

Redington, Inc.
Thomas Redington
Tel. +1 212-926-1733
tredington@redingtoninc.com